OMIC technologies and vaccine development: from the identification of vulnerable individuals to the formulation of invulnerable vaccines by Cotugno, Nicola et al.
Review Article
OMIC Technologies and Vaccine Development: From the
Identification of Vulnerable Individuals to the Formulation of
Invulnerable Vaccines
Nicola Cotugno ,1 Alessandra Ruggiero ,1 Veronica Santilli,1 Emma Concetta Manno,1
Salvatore Rocca ,1 Sonia Zicari,1 Donato Amodio ,1 Manuela Colucci ,2 Paolo Rossi,1
Ofer Levy,3,4 Federico Martinon-Torres ,5,6 Andrew J. Pollard,7 and Paolo Palma 1
1Academic Department of Pediatrics, Research Unit of Congenital and Perinatal Infection, Children’s Hospital Bambino Gesù,
Rome, Italy
2Laboratory of Nephrology, Department of Rare Diseases, Children’s Hospital Bambino Gesù, Rome, Italy
3Precision Vaccines Program, Division of Infectious Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, USA
4Broad Institute of MIT & Harvard, Cambridge, MA, USA
5Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago,
Santiago de Compostela, Galicia, Spain
6Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP), Instituto de Investigación Sanitaria de Santiago
and Universidade de Santiago de Compostela (USC), Galicia, Spain
7Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre,
Oxford, UK
Correspondence should be addressed to Paolo Palma; paolo.palma@opbg.net
Received 26 November 2018; Revised 1 March 2019; Accepted 6 March 2019; Published 28 April 2019
Guest Editor: Roberta A. Diotti
Copyright © 2019 Nicola Cotugno et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Routine vaccination is among the most effective clinical interventions to prevent diseases as it is estimated to save over 3 million
lives every year. However, the full potential of global immunization programs is not realised because population coverage
is still suboptimal. This is also due to the inadequate immune response and paucity of informative correlates of protection
upon immunization of vulnerable individuals such as newborns, preterm infants, pregnant women, and elderly individuals as
well as those patients affected by chronic and immune compromising medical conditions. In addition, these groups are
undervaccinated for a number of reasons, including lack of awareness of vaccine-preventable diseases and uncertainty or
misconceptions about the safety and efficacy of vaccination by parents and healthcare providers. The presence of these
nonresponders/undervaccinated individuals represents a major health and economic burden to society, which will become
particularly difficult to address in settings with limited public resources. This review describes innovative and experimental
approaches that can help identify specific genomic profiles defining nonresponder individuals for whom specific interventions
might be needed. We will provide examples that show how such information can be useful to identify novel biomarkers of safety
and immunogenicity for future vaccine trials. Finally, we will discuss how system biology “OMICs” data can be used to design
bioinformatic tools to predict the vaccination outcome providing genetic and molecular “signatures” of protective immune
response. This strategy may soon enable identification of signatures highly predictive of vaccine safety, immunogenicity, and
efficacy/protection thereby informing personalized vaccine interventions in vulnerable populations.
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1. Introduction
Vaccine-preventable disease (VPDs) pose an ongoing threat
to health worldwide which can be avoided by protective
and long-lasting vaccination coverage. Vaccines already
prevent 3 million deaths every year by providing immunity
against relevant pathogens. Nonetheless, current coverage
rates are suboptimal especially in the so-called “vulnerable
populations” (VPs) which include newborns, preterm infants,
pregnant women, and elderly individuals as well as those
patients affected by chronic and immune compromising
medical conditions [1]. There are various reasons for this
undervaccination, including lack of awareness of vaccine-
preventable diseases and uncertainty or misconceptions
about the safety and efficacy of vaccination among vulnerable
patients, parents, and healthcare providers. Furthermore, in
these VPs, the immune responses obtained with currently
available vaccines and schedules can be inadequate leading
to lower protection compared with healthy individuals [1, 2].
This situation represents a major health and economic bur-
den to society, which will become particularly difficult to
address in settings with limited public resources. As a conse-
quence, renewed attention and innovative strategies are
required to overcome the many challenges faced by public
health authorities to improving the efficacy of immunization
programs [3]. Two strategies are needed: (1) improve cur-
rent vaccination approaches by addressing education and
management of vaccine hesitancy and (2) develop innova-
tive tools that enable explanation of mechanisms behind
low or no responsiveness to current vaccine regimens in
these groups and design specific interventions accordingly
(i.e., booster doses of vaccines and/or tailoring adjuvantation
systems for vaccine formulations targeted to specific subpop-
ulations). In this review, we will mainly focus on innovative
genomic and transcriptomic tools that can identify specific
host characteristics defining nonresponder individuals for
whom specific interventions might be needed.
1.1. Low Vaccination Coverage in Vulnerable Populations:
Some Concerning Data. Low vaccination coverage in vul-
nerable groups increases the risk of developing vaccine-
preventable diseases with higher morbidity and mortality
[1]. The fact that vaccination rates among at-risk populations
remain low despite national and international recommenda-
tions indicates a continuing failure to provide appropriate
standards of care. One example is represented by maternal
immunization against influenza, pertussis, and tetanus,
which has the untapped potential of protecting the infant,
which remains low in European pregnant women (38-50%)
[4]. As a consequence, pertussis cases and outbreaks have
increased over the last few decades with ~1400 cases of
whooping cough documented in children < 6 months of age
in the US that lead to hospitalization in 44.3% of cases in
2016 CDC [5]. Additionally, infants < 6 months who experi-
ence influenza virus infection have the highest rates of hospi-
talization and death of all children especially if born preterm
[6]. Indeed, as current influenza vaccines are licensed for use
in those from 6 months of age, those less than 6 months of
age are too young to receive routine influenza vaccination
with protection relying on that conferred by a vaccinated
mother. Another example of low vaccination coverage is rep-
resented by elderly populations: in developing countries, the
need for better vaccination coverage of aging populations is
well recognised (reviewed in [1]). In the US, coverage among
people aged ≥65 years was 67% for the influenza vaccine in
the 2014–2015 and 55–60% for tetanus and pneumococcal
vaccines in 2013, while the coverage rate for herpes zoster
vaccination among those aged ≥60 years was only 24%. In
most other countries, rates are far lower (reviewed in [1]).
Furthermore, patients who are immunocompromised are
also undervaccinated [1, 7]. This diverse group of patients
includes patients with primary immunodeficiency, human
immunodeficiency virus (HIV) infection, transplantation,
cancer, asplenia, and autoimmune inflammatory diseases
treated with immunosuppressive medications (corticoste-
roid therapy, immunomodulatory medications, or biological
agents) [8–11].
Vaccine hesitancy, access to immunization, and inade-
quate response to vaccination are three distinct and equally
concerning contributors to poor vaccination coverage in the
global population as well as in the vulnerable population.
For these and other reasons, personalized vaccine strategies
could be considered to improve vaccination coverage and
outcome as discussed below.
1.2. Reasons to Personalize Vaccine Intervention in
Vulnerable Populations. High vaccination coverage is para-
mount to ensure global health, and it can be achieved by
promotion of vaccination and by the design of effective
vaccine. However, vulnerable populations consistently gen-
erate vaccine-specific immune responses that are consider-
ably weaker than those of the healthy immunocompetent
population [1, 2, 12–15]. We previously demonstrated that
patients with chronic granulomatous disease (CGD) pres-
ent a significantly reduced measles-specific antibody levels
and antibody-secreting cell number indicating poor ability
to maintain long-term memory in these patients [16]. Sim-
ilarly, we demonstrated that 19% of kidney transplanted
patients (TPs) on immunosuppressive therapy experienced
loss of vaccine-induced immunity against measles after
two doses of live attenuated measles vaccine at 13 months
and 6 years of age [17]. Furthermore, we found a positive cor-
relation between the antibody titres and the time elapsed
between vaccination and transplant, demonstrating that
patients transplanted close to vaccination had lower measles
antibody titre than patients vaccinated earlier before trans-
plantation. Reversing this situation is likely to require a broad
range of interventions. For example, financial incentives,
patient reminders, and patient recall systems can improve
vaccination rates and are more readily implemented in
high-income country settings [18]. Nonetheless, there is lack
of harmonized research data that can provide meaningful
evidence on the efficacy and safety of vaccination in this
group. Indeed, most vaccine indications in special and vul-
nerable groups derive from extrapolations, assumptions, or
postlicensure studies in healthy populations.
Generating and analysing clinical, laboratory, system
biology “OMICs,” and computational data are needed to
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inform selection of patients at risk for vaccine failure and
specifically tailor vaccination approaches in these groups.
The number of patients who are immunocompromised is
increasing [19], and the suboptimal vaccination coverage in
this growing number of people represents a substantial health
and economic burden to society, as discussed above. Further-
more, vaccine-preventable infectious diseases have been
reported in these groups despite a history of vaccination
[19–24]. Such cases are often the first demonstrable sign of
inefficacy of the current vaccination strategies in specific
populations within a community. This situation has gener-
ated major concern in the World Health Organization
(WHO) that is promoting strategies (The Guide to Tailoring
Immunization Programmes (TIP)) [3] to enhance efficient
vaccination in newborns and children, with a plan to extend
this action to individuals within other vulnerable popula-
tions. Although they are useful, such recommendations are
based on expert opinions and extrapolated from data pro-
duced in healthy people and not developed based on vaccine
immunity data in vulnerable populations.
2. Modern System Biology Tools to Characterize
Immune Responses to Vaccination
Despite the fact that conventional immunological assays,
such as ELISA, ELISpot, flow cytometry, and neutralization
assays, have supported all previous researches [25–33],
the toolkit of the modern immunologists now includes a
broad range of “OMICs” technologies [34–37], such as
high-throughput sequencing of DNA (DNA-seq), RNA
(RNA-seq), transcriptomic assays, microarrays, epigenetics,
and high-resolution mass spectrometry proteomics and
metabolomics [22, 38–43]. Data produced by these differ-
ent approaches will enable prediction of patients likely to
have a poor outcome from vaccination with respect to
safety and/or immunogenicity (Figure 1). The amount of
information provided by these experimental approaches rep-
resent considerable experimental data analysis challenges
[44]; therefore, sophisticated bioinformatic tools are under
development for data integration [45].
2.1. High-Throughput Sequencing of DNA and RNA
(Transcriptomic Assays). High-Throughput Sequencing of
DNA and RNA (Transcriptomic Assays) has helped to iden-
tify specific mechanisms that regulate gene expression and
associated with differentiation and functionality of different
cell lineages including immune cells [39, 46]. For example,
Reif et al. identified and validated three SNPs associated with
adverse events to smallpox vaccine in healthy vaccinia virus-
naïve individuals [47]. The study demonstrated how com-
mon genetic variants can be related to a complex clinical
phenotype, and prescreening is needed to predict adverse
events. Poland and colleagues identified genetic variations
in HLA and non-HLA genes associated with non- or hyper-
immune phenotypes after measles, mumps, rubella, and
smallpox, proposed as “genetic blueprints to guide personal-
ized vaccination regimens” [48, 49]. Other studies have char-
acterized the sequences of heavy and light chains of the
antibody following vaccination against pathogens such as
influenza and tetanus, with the ultimate aim of engineering
responsive antibodies that could be administered to support
immunization [50, 51].
Furthermore, DNA sequencing has helped to identify
and describe stimulus-induced epigenetic events, paving the
way to a new research area: epigenomics. In particular,
DNA methylation [52, 53] events are associated with (a) dif-
ferential expression of proinflammatory (IL12p70, IL-1β,
IL-6, and TNF-α) and regulatory (IL-10) cytokines and
costimulatory molecules (CD80, CD86, and CD40) in antigen-
















Figure 1: Conventional and system biology “OMICs” technologies [35] currently available to predict vaccine-induced immune response.
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functional responses and polarization, influencing the innate
immune system through macrophage tolerance and training
[54]; and (c) modulation of T and B cell differentiation and
maturation [54]. Accordingly, recent studies have explored
the effect of epigenetic regulation in response to vaccination.
For example, individuals showing antimycobacterial activity
following BCG vaccination had reduced the presence of meth-
ylation events in promoters associated with immune responses
in PBMC [55]. In particular, at 3 weeks after vaccination, 540
promoters displayed a more than 5-fold loss of methylation
in the responders, whereas only 20 promoters were losing
methylation in the nonresponders. Furthermore, at 4 and 8
months, after vaccination, a substantial gain of methylation
was observed in the nonresponders. On the contrary, a group
of hypomethylated CpGs has been associated with lower
humoral immune response to influenza vaccination [56].
Similarly, another study by Marsit et al. [57] demonstrated
a small but statistically significant reduction in the methylation
of peripheral blood repetitive elements in an HIV-exposed
and antiretroviral therapy- (ART-) exposed pediatric cohort
when compared with an HIV-exposed and combined ART-
unexposed cohort. However, data are still scarce and often con-
tradictory, and efforts are needed to define the power of specific
methylation marks in predicting vaccine responses.
The combination of flow-based sorting and microfluidic
transcriptomic assays (Fluidigm) has enabled dissection of
transcriptional signatures of immune cell subsets particularly
involved in the memory response upon vaccinations. The low
number of cells needed for these assays has made such stud-
ies feasible in pediatric cohorts and provides the possibility to
investigate gene expression on purified memory subsets
rather than in the highly variable pool of PBMCs allowing
the analysis of low abundance transcripts. Such methodol-
ogy increases the specificity of transcriptional characteris-
tics found in peculiar cell subsets which are involved in
the immune memory response but are quantitatively rare
in the pool of PBMCs [58]. With such strategy, Cotugno
et al. have recently investigated the prevaccination gene
expression signatures of lymphocyte subsets in groups of
HIV-1-infected children differentially responding to trivalent
influenza vaccination (TIV). A 25-gene signature in resting
memory (RM) B cells (CD27+CD21+) distinguished vac-
cine responders from nonresponders (NR). In fact, prevac-
cination RM B cells of responders demonstrated a higher
expression of gene sets involved in B cell adaptive immune
responses (APRIL, BTK, BLIMP1) and BCR signalling
(MTOR, FYN, CD86) when compared with NR. We further
investigated the variation of gene expression of peripheral T
follicular helper (pTfH) cells after in vitro stimulation with
H1N1 peptides. In line with previous FACS and ELISA
results [59], our analysis revealed that the ability to upregu-
late the gene expression of interleukin-21 (IL-21) within
pTfH after in vitro stimulation was strongly associated with
H1N1-specific B cell responses postvaccination [60]. These
results suggest that the targeted transcriptional evaluation
of B and T cell subsets at the time of vaccination may identify
predictive correlates of vaccine responses in this population.
Other advantages of this analytical tool account for contain-
ment of costs when compared to RNA-seq (approximately
1/25) and to DNAmicroarray (approximately 1/10). In addi-
tion, the integration and the analysis of targeted multi-
plexed RT-PCR (e.g., Fluidigm) rather than “big data”
deriving from RNA-seq need less sophisticated bioinfor-
matic expertise which may enhance clinical applicability
of such analysis.
On the other hand, the selection of specific gene sets for
analysis also represents a limitation. Indeed, whole tran-
scriptome or genome analysis may provide more specific
and unbiased information on molecular mechanisms under-
lying vaccine-induced reactogenicity and immunogenicity.
In the context of vulnerable populations, such information
may provide important input into discovery of specific path-
ways, inadequately engaged by current vaccines, which may
inform future targeted adjuvant strategies. In this context,
the interindividual variability in vaccine responses or reac-
tion upon vaccinations has been investigated, and several
polymorphisms of genes, including HLA, KIR, MICA, and
BTN genes, were identified that impact immune responses
to immunization against hepatitis B [61–63], influenza [61],
and smallpox [64, 65]. Possible mechanisms underlying such
correlation presumably refer to the selectivity of specific HLA
types to naturally process particular vaccine peptides and
present to T and B cells. Such peptides are enriched by spe-
cific particles and adjuvants and are now being utilized in a
reverse-engineering strategy to develop peptide-based candi-
dates for measles and mumps vaccines [66]. Ovsyannikova
et al. recently reported how specific coding polymorphisms
in Toll-like receptor (TLR) genes are associated with immu-
nogenicity of measles vaccine [67, 68]. Although these find-
ings represent great steps towards the design of personalized
peptides and adjuvants in the immunization schedule for
NR, most of these studies have been conducted in healthy
individuals (reviewed in [69]). Indeed, such approaches have
only rarely investigated vaccine-related immunogenicity and
adverse events in vulnerable populations (especially in the
elderly) showing how signatures of NR found in healthy
individuals are only partially applicable to such populations
[70]. However, the few studies conducted on vulnerable pop-
ulations showed that the genetic signatures associated with
lack of vaccine immunogenicity in healthy individuals were
not fully powerful when applied to vulnerable populations.
Thus, there is an urgent need for more vaccinology studies
in these vulnerable populations.
To improve robustness and power of transcriptomic data,
gene set enrichment analyses (GSEA) have been developed
in order to analyse genes within their functional group or as
being part of the same signalling pathway. In line with this
approach, increasing numbers of functional annotation tools
available online free of charge can identify enriched biological
themes—Gene Ontology (http://geneontology.org), DAVID
(http://david.abcc.ncifcrf.gov), http://www.pathjam.org, and
http://genemania.org—and functionally related gene groups.
In a different approach, the whole transcriptome was
implemented to describe factors correlated to vaccination
immunogenicity in the blood cells of humans few days after
yellow fever vaccination [42]. In particular, the authors found
enrichment of genes promoting apoptosis including GSTP1,
STAT4 inhibitor, IL17D, and ZNF-148 (also known as
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ZBP-89) (reviewed in [71]). This approach was further
explored to define possible correlates of adaptive and innate
immunity able to predict immunogenicity of influenza
vaccination (live attenuated influenza vaccine and TIV)
[37]. Both Nakaya et al. [40] and Tsang et al. [43] found
that the calcium/calmodulin-dependent kinase IV (Camk4)
gene expression modules could be used as a predictor of
low antibody titres upon influenza vaccination. In order
to define the vaccine specificity, Li et al. [36] compared five
5different vaccinations and found three different signa-
tures of immune response according to the type of vacci-
nations used. It is still unclear however, whether gene
signatures of vaccine immunity should be investigated in
selected lymphocyte subsets or in antigen- (Ag-) specific
cells. Technological advances in single-cell analysis allow
for deeper interrogation of cellular signatures in cell pop-
ulation with diverse functions, such as Ag-specific cells in
memory cell compartments.
Among these, single-cell RNA sequencing (scRNA-seq)
[72–74] has provided insights on key processes in immune
cell development and differentiation [73, 74], on haemato-
poietic pathways [75], and on gene regulatory networks that
predict immune function [76]. There are multiple scRNA-
seq approaches, the most current version being massively
parallel RNA single-cell sequencing (MARS-seq), Fluidigm
C1 single-cell full length messenger RNA (mRNA) sequenc-
ing, switching mechanisms at the 5′ end of RNA template
(SMART-seq2), and 10x genomic chromium single-cell
DNA sequencing (herein referred to as 10x cell sequencing
(reviewed in detail by [74])). Among those, the most prom-
ising at the moment is the 10x cell sequencing (described in
[77]). This cutting-edge technology performs rapid droplet-
basedencapsulation of single cells using a gel bead in
emulsion (GEM) approach. Each gel bead is labelled with
oligonucleotides that consist of a unique barcode, a 10 bp
unique molecular identified and an anchored 30 bp oligo-
dT. The high-throughput system is designed to enable
analysis of rare cell types in a sufficient heterogeneous bio-
logical space avoiding the cell sorting step with reduced waste
of the precious clinical sample. Similar to other droplet-based
methods, clinical samples must be handled with caution
in order to minimize perturbation of existing cellular charac-
teristics [78]. Importantly, this method also enables cellular
indexing of transcriptomes and epitopes using DNA-
barcoded antibodies by Cellular Indexing of Transcriptomes
and Epitopes by sequencing (CITE-seq) of thousands of sin-
gle cells [79]. Accordingly, CITE-seq could find major appli-
cability in immunology for sequencing of antigen-specific
cells by multiplexing specific antigenic protein markers.
2.2. Proteomics and Metabolomics. Although high-
throughput technologies can provide a valuable “snapshot”
of the transcriptional levels of genes inside the cells, the inter-
actions among those genes cannot be fully captured if the
above described tools are uniquely used to generate lists of
genes or pathways associated to a specific cellular activity.
Indeed, it is the functional relationships between genes, pro-
teins, and metabolites that may help us to better understand
biological processes involved in cellular responses.
In this optic, the identification of the subset of proteins
and peptides involved in the immune response could be piv-
otal to unravel mechanisms supporting a successful vaccina-
tion outcome [80]. Targeted protein analysis assays (e.g.,
ELISA and WB) only allow for quantification of a certain list
of protein candidates limiting the proteomic discoveries. To
overcome this hurdle, different high-throughput methods
have recently been developed. Mass spectrometry- (MS-)
based proteomics is the most widely used approach, and
it has been essential to define the major histocompatibility
complex (MHC) in the context of T cell profiling [81] as
well as the antigenic determinants triggering B cell activity
[82–84]. As the MS method is not limited to the use of pre-
defined proteins, it has become the method of choice for
protein discoveries across different fields as already been
extensively described somewhere else [80]. More recently,
Bennike et al. [85] have optimized use of as little as 1μl
of blood plasma for a high-throughput MS approach with
bioinformatic analysis employing Spectronaut. This inno-
vative, cost-effective high-throughput technology has, for
example, supported the discovery of 16 serum proteins
predicting chronic pancreatitis. Indeed, low sample input,
high throughput, and robust proteomic depth render this
method attractive for large diagnostic studies aiming at
the identification of protein biomarkers in different clinical
and scientific settings.
Evaluation of metabolomic signatures can be an addi-
tional mass spectrometery-based tool to capture perturba-
tion of the immune system after a vaccination and translate
such information as potential new biomarkers of vaccine
immunogenicity. McClenathan et al. [86] used the nuclear
magnetic resonance metabolomic approach to characterize
specific metabolites predicting adverse reaction following
vaccination. These studies provided a set of metabolites asso-
ciated with the vaccine outcome that can be used in the clin-
ical practice for identification of vaccine nonresponder
individuals. Furthermore, Li et al. applied a multidisciplinary
approach to define immunological response to herpes zos-
ter (shingles) by studying transcriptomics, metabolomics,
plasma cytokines, and cell phonotypes in blood samples.
2.3. Data Integration. OMIC approaches have changed
perspectives and dimension of data to be handled and inter-
preted. Indeed, most of these sophisticated approaches often
require big sample volume, which may hurdle the large-scale
applicability of the methods. The Human Immunology Pro-
ject Consortium (HIPC, https://www.immuneprofiling.org
[87]) program has developed novel analytic tools to integrate
the information derived from OMICs, in vitro assays, and
functional assays to define vaccine responsiveness.
The overwhelming amount of data represents both a pre-
cious source and a hurdle towards the design of rule-driven
precision medicine [34]. Indeed, there is the need for more
complex algorithms capable of integrating data from differ-
ent system biology approaches that will consequentially be
implemented, tested, and validated in order to generate a
clinical tool that can support the personalization of vaccina-
tion strategy. Accordingly, novel research approaches in the
last two decades have led to partnerships of basic scientists,
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bioinformaticians, and physicians to appropriately interpret
data. With this aim, specific tools have been developed to
enable gene set enrichment analyses (GSEA) in order to
improve robustness, power, and readability of transcriptomic
data, as mentioned above. Furthermore, there are various
modelling frameworks that can be applied which range from
simple linear regression models to advanced and computa-
tionally expensive feature selection methods for identifying
predictive signatures (reviewed in [88]). For example, net-
work modelling provides a powerful way to uncover the
organizing principles and regulatory elements of cellular
networks and how these networks modulate immunological
responses to vaccination (reviewed in [88]). Additional
tools such as Network Analyst and DIABLO (Data Integra-
tion Analysis for Biomarker discovery using Latent variable
approaches for ‘Omics studies) have been employed to
understand multidimensional data across multiple assay
platforms [45].
3. Ebola and Influenza Vaccines: Two Successful
OMIC Examples of Applied
System Vaccinology
3.1. Ebola. Rechtien et al. applied a system vaccinology
approach to unravel if the early immune response towards
Ebola vaccine rVSV-Zaire Ebola virus (ZEBOV) predicts
the generation of anti-Ebola virus (EBOV) glycoprotein-
(GP-) specific antibody responses [89]. The study employed
blood samples from days 0, 1, 3, 7, and 14 postvaccination
to investigate changes in cytokine levels, innate immune cell
subsets, and gene expression. Integrative statistical analyses
with cross-validation identified a signature of 5 early innate
markers correlating with antibody titres on day 28. Among
those, interferon-γ-inducible protein 10 (IP-10) on day 3
and MFI of CXCR6 on NK cells on day 1 were independent
correlates. Consistently, they found an early gene expression
signature linked to IP-10. This comprehensive characteriza-
tion of early innate immune responses to the rVSV-ZEBOV
vaccine in humans revealed immune signatures linked to
IP-10. These results suggested correlates of vaccine-induced
antibody induction and provide a rationale to explore strate-
gies for augmenting the effectiveness of vaccines through
manipulation of IP-10.
3.2. Influenza. In line with our data on influenza previously
discussed [22, 60, 90], Franco and colleagues studied a
homogenous population of 199 healthy male volunteers with
trivalent influenza vaccines [38]. They performed an integra-
tive genomic analysis of the human immune response to
influenza vaccination exploring association of genotype to
gene expression, gene expression to antibody titre, and geno-
type to antibody titre. They identified 20 genes associated
with a transcriptional response to vaccination, significant
genotype effects on gene expression, and correlation between
the transcriptional and antibody responses. The following
loci were found to have the strongest evidence of genetic var-
iation influencing the immune response to the vaccine:
TAP2, SNX29, FGD2, NAPSA, NAPSB, GM2A, C1orf85,
JUP, FBLN5, CHST13, DIP2A, PAM, D4S234E, C3AR1,
HERC2, LST1, LRRC37A4, OAS1, RPL14, and DYNLT1.
The results showed that variation at the level of genes
involved in membrane trafficking and antigen processing sig-
nificantly influenced the human response to influenza vacci-
nation. Overall, this study identified crucial genes in the
humoral response to vaccination suggesting such marks as
logical biomarkers predicting the vaccination outcome. Such
examples show how OMICs can be used to predict vaccina-
tion outcome in order to identify nonresponders.
4. Rationalising the Development of Adjuvants
as Possible Strategy to Personalize Vaccines
In order to improve the efficacy of the vaccine, adjuvants
can be added to antigens in order to stimulate in a selective
way the different routes of innate and adaptive immunity
[34]. The use of optimized adjuvanted formulations may
overcome host characteristics that limit vaccine response
and possibly favour personalized vaccine interventions.
Adjuvants can be crucial to enhance immune response in
low-responder individuals. Reference [91] explored the poten-
tiality of TLR8 agonist as adjuvant for BCG and pneumococcal
vaccination in newborns. TLR8 agonist-encapsulating poly-
mersome triggered dendritic cell (DC) responses enhancing
vaccine immunogenicity, thus suggesting TLR8 potential
for early-life immunization against intracellular pathogens.
Adjuvants may be delivered as components of microorgan-
isms. For example, Neisseria meningitidis lipopolysaccharide
(LPS) is a good example. Mehta et al. demonstrated that
LPS exhibited differential adjuvant properties when formu-
lated as native outer membrane vesicles (nOMVs). nOMVs
enhanced immunogenicity suggesting that they may be an
effective adjuvantation approach for future meningococcal
protein vaccines. [92].
By combining OMIC technologies, data on vaccine
immunity in groups with special vaccination needs, and
adjuvant screening and development, we can increase our
knowledge on mechanisms of vaccine hyporesponsiveness
and how to overcome it. In the near future, these efforts
will enable a new generation of adjuvants designed to stim-
ulate, in a selective way, the different routes of innate and
adaptive immunity.
5. Future Perspectives: From Vulnerable One-
Fits-All Vaccines towards Invulnerable One-
Fits-One Vaccines
Vaccines have greatly improved life expectancy by con-
taining and in some cases eradicating diseases causing
pathogens. Preventing vaccine disease has great impact
not only on global health but also on the economy of
the society 5by reducing hospitalization costs. Originally,
one single vaccine was developed to target the global pop-
ulation accounting for limited cases of vaccine failure,
even though data on vaccine failure was scarce especially in
vulnerable populations (Figure 2). However, this approach
is becoming less successful with the expansion of a popu-
lation of immunocompromised individuals that fail to
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respond to standard vaccination schedules and composi-
tions. Therefore, vaccinology is in part focused on tailor-
ing specific interventions for these vulnerable individuals
in the near future.
At the moment, there are some indications on how to
optimize vaccine strategies in vulnerable individuals. How-
ever, interventions are still decided upon evidence deriving
from study of healthy individuals or upon expert’s opinion.
To improve on this current approach, current efforts aim to
better characterize the vulnerable population, which can be
integrated to generate predictive bioinformatic models for
precise early identification of nonresponders. System biology
studies are already revealing genetic and molecular “signa-
tures” of protective immune response in healthy population
[93]. In the near future, we trust that it will be possible to
narrow such signatures to highly predictive assays of effica-
cy/effectiveness and identify precise correlates of protection
in vulnerable groups (Figure 2).
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Figure 2: The figure shows changes in populations’ composition with special vaccination needs over time. Traditionally, only elderly people
and infants were considered vulnerable. During this time period, little scientific evidence regarding vaccine responses of different
populations was available, and a single vaccination schedule was proposed for all (empirical medicine). Currently, an increasing number
of people with special vaccination needs, such as immunocompromised patients and pregnant women, are considered in specific vaccine
programs based on expert opinion and on extrapolated data from healthy individuals (stratified medicine). In the near future, the
increased number and life expectancy of groups with special vaccination needs will lead to large-scale population studies. This approach
will provide robust scientific evidence and new correlates of protection and safety. As a result, rationalisation of vaccine strategies
(antigens, adjuvants, etc.) and personalization of approaches will increase vaccination efficacy and safety in these populations within a
framework of personalized medicine.
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